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LADA and CARDS: A Prospective
Study of Clinical Outcome
in Established Adult-Onset
Autoimmune Diabetes
Diabetes Care 2014;37:1643–1649 | DOI: 10.2337/dc13-2383
OBJECTIVE
Diabetes-associated autoantibodies can be detected in adult-onset diabetes, even
when initially non–insulin requiring, i.e., with latent autoimmune diabetes. We
aimed to identify adult-onset autoimmune diabetes in patients with established
“type 2 diabetes” participating in the Collaborative Atorvastatin Diabetes Study
(CARDS) to characterize their phenotype and clinical outcome.
RESEARCH DESIGN AND METHODS
We prospectively studied 2,425 European patients with presumed type 2 diabetes
(mean age 62 years, diabetes duration 7.9 years) for outcomes at 3.9 years after
randomization to either atorvastatin or placebo. Subjects were screened for
autoantibodies to GAD (GADA), insulinoma-associated antigen-2 (IA-2A), and
zinc-transporter 8 (ZnT8A).
RESULTS
A total of 173 patients (7.1%) had GADA, of whom 11 (0.5%) and 5 (0.2%) were also
positive for IA-2A and ZnT8A, respectively. At baseline, 44% of GADA-positive
patients were not on insulin. Fewer autoantibody-positive than autoantibody-
negative patients hadmetabolic syndrome (64 vs. 80%), and more were on insulin
(56 vs. 17%) (P < 0.0001 for each) without lower HbA1c (69 mmol/mol [8.5%] vs.
62 mmol/mol [7.8%]). The frequency of microvascular and macrovascular events
was similar in both cohorts, independent of atorvastatin.
CONCLUSIONS
Adult-onset autoimmune diabetes was prevalent, even in patients with established
diabetes presumed to have type 2 diabetes. After 11.8 years’ diabetes duration,
nearly half the patients with autoimmune diabetes were not on insulin treatment
and almost two-thirds had metabolic syndrome. The type of diabetes, whether
autoimmune diabetes or type 2 diabetes, did not impact the risk of microvascular
disease.
Adult-onset autoimmune diabetes has many of the immunogenetic features of
childhood-onset autoimmune diabetes, and the deﬁnition of autoimmune type 1
diabetes encompasses both forms of the disease. But the clinical phenotype of
adult-onset autoimmune diabetes is broad and, at diagnosis, includes patients
with frank insulin-dependent diabetes as well as patients with non–insulin-requiring
diabetes. These latter patients are designated as having latent autoimmune
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diabetes in adults (LADA)whennot started
on insulin treatment within 6 months of
diagnosis. Recent large studies indicate
that theproportion (7–10%) of adult-onset
diabetic patients who have autoimmune
diabetes, including LADA, is such that this
is themost prevalent form of autoimmune
type 1 diabetes (1,2). Nonetheless, we
know little of the natural history of this
form of autoimmune diabetes.
To explore the natural history of adult-
onset autoimmune diabetes (LADA) in a
large cohort of patients with established
diabetes, we determined diabetes-
associated autoantibodies from patients
in the Collaborative Atorvastatin Diabetes
Study (CARDS). CARDS was a multicenter
trial of atorvastatin for the primary pre-
vention of cardiovascular disease (CVD),
which also estimated microvascular com-
plications in adult patients with pre-
sumed type 2 diabetes. These patients
had established diabetes of some years
duration and were followed for an aver-
age of 3.9 years until the study was ter-
minated (3,4).
Previous studies of LADA have indi-
cated that this form of adult-onset auto-
immune diabetes at the time of diagnosis
is characterized by the predominant pres-
ence of autoantibodies to GAD (GADA),
reduced frequency of metabolic syn-
drome, and an increased likelihood of
progression to insulin treatment (5). Out-
come studies, to date, have been under-
powered because of short duration of
review and limited numbers of cases
under review (6–9). We now present
an initial analysis of the CARDS cohort
to address these shortcomings.
RESEARCH DESIGN AND METHODS
Study Population
CARDS was a double-blind, randomized,
placebo-controlled, multicenter trial of
atorvastatin (10mg/day) for the primary
prevention of CVD in type 2 diabetes
(3,4). Type 2 diabetes was diagnosed
as deﬁned using the 1985 World Health
Organization (WHO) criteria. The study
received ethics approval both centrally
and at each participating institution, and
each patient gave written informed con-
sent. The study included 2,838 random-
ized patients (68% men) between 40
and 75 years of age (mean age 62 years
and mean duration of disease 7.9 years;
median 6 years [25th–75th percentile
3.0–11.0) who took at least one dose
of the study drug. The primary end point
of the trial was the ﬁrst acute coronary
heart disease event (myocardial infarc-
tion, hospitalized unstable angina, acute
coronary heart disease [CVD]), coronary
revascularization procedure, or stroke.
In addition, information about all causes
of deathwas collected. LADAwas deﬁned
as reported by presence of diabetes-
associated autoantibodies in patients
(age 30–75) without insulin therapy for
at least 6 months postdiagnosis.
Inclusion Criteria
Patients included in the study were free
of macrovascular disease, with serum
LDL cholesterol concentrations #4.14
mmol/L (#160 mg/dL) and fasting se-
rum triglyceride concentrations #6.78
mmol/L (#600 mg/dL). In addition,
study participants were required to
have at least one of the following car-
diovascular risk factors: hypertension on
treatment, systolic blood pressure
$140 mmHg, or diastolic blood pres-
sure $90 mmHg on two successive oc-
casions; any retinopathy as assessed by
early screening according to the Na-
tional Institute for Health and Care
Excellence guidelines (www.nice.org
.uk); proteinuria including microalbumin-
uria (elevated 30–300 mg/day), used
as an indicator of progressive renal
failure; or current smoking. Reti-
nopathy was deﬁned as any of the
following: nonproliferative retinopa-
thy, preproliferative retinopathy, pro-
liferative retinopathy, maculopathy,
advanced diabetic eye disease, or his-
tory of photocoagulation.
The trial was terminated 2 years ear-
lier than planned at the request of the
Safety Committee because of the clear
beneﬁt of active treatment (P , 0.001,
two-tailed test) (3,4). The median pa-
tient participation in the trial was 3.9
years.
Laboratory Methods
Blood samples from patients were col-
lected at the time of inclusion into the
study, and serum samples were stored at
2208C prior to analysis. All patients were
tested in a central laboratory (London) for
serumGADA and serum autoantibodies to
IA-2 (IA-2A) and ZnT8 (ZnT8A) on all GADA-
positive samples and randomly selected
GADA negative samples, using established
radioimmunoprecipitation assays (10,11).
Each assay included serially diluted sera
from a prediabetic individual. These in-
house standards were diluted to an end
point; a separate positive serum sample
(equivalent to the WHO standard of 250
WHO units) was used as an in-house
control to standardize each assay for
unit calculation. All GADA-positive sam-
ples and a randomly selected group of
GADA-negative samples (n = 200) were
tested for IA-2 (IA-2A) and ZnT8 (ZnT8A).
Positive results were duplicated, reduc-
ing false positives to ,0.02%. GADA
positivity was further divided into high
(.200 units) or low (40–200 units) titer.
To further differentiate autoantibody
positivity, according to autoantibody
titers on the whole cohort we used the
QQ plot analysis. The QQ plot conﬁrmed
the selection of the laboratory-based
cutoff for positivity at 40 WHO IU in
this cohort based on the end point dilu-
tion of the standard curve used indepen-
dently, as well as identiﬁed two distinct
cohorts among GADA-positive subjects,
with an inﬂection at 40 (GADA low) and
another at 200 WHO IU (GADA high). In
the 2008Diabetes Antibody Standardiza-
tion Program (DASP) (12,13), London, as-
say characteristics to identify known
positive samples were as follows: GADA
sensitivity 72%, speciﬁcity 95%, andIA-
2A sensitivity 68%, speciﬁcity 98%. In
the latest DASP 2010 program, GADA
sensitivity was 90% and speciﬁcity 93%,
IA-2A sensitivity 68% and speciﬁcity 95%,
and ZnT8A sensitivity 60% and speciﬁcity
88% (data unpublished). The pJH4z1 probe
for ZnT8A was provided by Dr. J. Hutton
(University of Colorado, Denver, CO).
Statistical Analysis
For continuous variables, the compari-
sons between GADA groups were based
on the t test as univariate analysis and
ANCOVA as multivariate analysis that ad-
justed for age, duration of diabetes,
and sex. Similarly, for categorical vari-
ables, the x2 test and logistic regression
were used, respectively, in univariate
and multivariate analyses. Owing to a
highly skewed distribution, triglycerides
and C-reactive protein (CRP) were log
transformed before the comparison. All
analyses were performed using SAS.
Nominal P values were reported without
adjustment for multiplicity. A P value
,0.05was considered statistically signif-
icant. The study protocol is in accor-
dance with the Declaration of Helsinki
and was approved by local ethics com-
mittees in each study area. Informed
written consent was obtained from all
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subjects before blood sampling. The
study was approved by the U.K. National
Research Ethics Committee (reference
MREC 199/2/76).
RESULTS
Of 2,838 samples from the CARDS study
cohort, 2,425 (representing those sam-
ples in which there was sufﬁcient serum
for analysis) were tested for GADA, and
of these 173 (7.1%) were GADA positive.
Other diabetes-associated autoantibod-
ies were only found in GADA-positive
cases of which 16 (0.7%) were positive
for IA-2A and 6 (0.2%) positive for
ZnT8A; one patient was positive for all
three autoantibodies (Fig. 1). GADA-
positive patients, in comparison with
the GADA-negative patients, tended to
be younger at diagnosis (51.5 vs. 55.0
years; P , 0.01) and leaner (27.3 6
3.7 vs. 28.9 6 3.5 kg/m2; P , 0.001)
with a longer disease duration (10.2 6
7.0 vs. 7.6 6 6.2 years; P , 0.0001)
(Tables 1 and 2). The prevalence of
LADA was higher in patients diagnosed
with diabetes at a younger age, and
GADA+ patients were 3.5 years younger
(P = 0.01) (Table 1). Furthermore, GADA
was more often detected in patients di-
agnosed with diabetes at a younger age:
30–40 years old age-group 12% com-
pared with those $61 years or older
4.7% (P = 0.0024, data not shown).
These characteristics of GADA-positive
patients were true irrespective of GADA
titer.
In keeping with decreased metabolic
syndrome (deﬁned by International
Diabetes Federation [IDF] criteria [14])
in participants who were GADA positive,
the waist measurement, BMI, and fast-
ing triglycerides were lower and HDL
Figure 1—A total of 173 individuals were positive for GADA, and 16 of these were positive for a second antibody (11 were IA-2A positive, and 6 were ZnT8A
positive). One individual was positive for all three antibodies. None of the GADA-negative samples tested as a control group were positive for IA2A or ZnT8A.
Table 1—Clinical characteristics at baseline of GADA+ and GADA2 individuals
Baseline GADA+ GADA2 P
n 173 2,252
Age at diagnosis (years) 51.5 6 9.3 55.0 6 9.4 0.01
Diabetes duration (years) 10.2 6 7.0 7.6 6 6.2 ,0.0001
BMI (kg/m2) 27.3 6 3.6 28.9 6 3.5 ,0.0001
HbA1c (mmol/mol) 69 6 16 62 6 15 ,0.0001
SBP (mmHg) 142.1 6 17.4 144.0 6 15.7 0.15
DBP (mmHg) 81.6 6 9.1 82.9 6 8.3 0.18
LDL cholesterol (mmol/L) 3.1 6 0.7 3.0 6 0.7 0.1
HDL cholesterol (mmol/L) 1.6 6 0.4 1.4 6 0.3 ,0.0001
CRP (mg/L) 2.8 6 5.1 3.1 6 6.4 0.13
Apolipoprotein A1 (mg/dL) 162.6 6 30.1 152.0 6 27.8 ,0.0001
Apolipoprotein B (mg/dL) 112.7 6 23.8 116.3 6 24.0 0.05
Atorvastatin treatment 49.1 51.0 0.52
High waist measure (WHO) 67.6 83.0 ,0.0001
Metabolic syndrome (IDF deﬁnition) 63.6 80.4 ,0.0001
Diet treated alone 5.8 15.7 0.02
Oral diabetes therapy 38.1 67.3 ,0.0001
Insulin treated alone 56.1 17.1 ,0.0001
Albuminuria+ (macro/micro) 10.4 11.6 0.6
Any retinopathy 35.3 29.4 0.7
Proliferative retinopathy 10.4 6.3 0.2
Current smoker 27.8 21.8 0.03
Use of BP tablets 59 67.4 0.04
Data are percent unless otherwise indicated. The clinical characteristics of the individuals in
accordance with GADA positivity are presented as mean 6 SD. The data were processed by
multivariate analysis, adjusted for age, duration of diabetes, and sex. BP, blood pressure.
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cholesterol higher compared with those
who were GADA negative (all P, 0.001).
LDL cholesterol and blood pressure was
similar in the two groups. Nonetheless,
63.6% of GADA-positive patients had
metabolic syndrome compared with
80.4% of GADA-negative patients (P ,
0.0001) (Table 1)ddifferences even ap-
parent in patients with low-titer GADA
(Table 2).
At baseline, GADA-positive patients
were more often on insulin therapy than
GADA-negative patients with diabetes
(56.1% vs. 17.1%; P , 0.0001) (Table 1)
irrespective of GADA titer (Table 2). At 3.9
years’ follow-up analyses of insulin na¨ıve
patients, the cumulative use of insulin in
the GADA-positive patients was higher
than that in the GADA-negative patients
(16.2% [95% CI 0.6–21.7] vs. 5.1% [4.2–
6.0];multivariate analysis, odds ratio [OR]
3.1 [95% CI 2.0–4.9], P, 0.0001) (Tables
3 and 4). Similarly, the GADA-positive pa-
tients were leaner at baseline and follow-
up (BMI 27.26 3.7 and 26.46 3.8 kg/m2,
respectively) than GADA-negative pa-
tients (BMI 28.8 6 3.7 and 29.0 6
3.8 kg/m2) (P , 0.002). Furthermore,
despite the higher likelihood of insulin
treatment in the GADA-positive patients,
glycemic control (HbA1c) remained similar
if not worse in patients treated with
insulin (univariate P = 0.0016; multivari-
ate P = 0.07). The history of smoking was
not reduced in GADA-positive cases as
previously reported (15) (Table 1).
There was no difference in the fre-
quency ofmicrovascular disease between
the groups. Of 173 GADA-positive pa-
tients, 28 (16%) developed either albumin-
uria or proliferative retinopathy compared
with 315 (14.0%) GADA-negative type 2
diabetic patients (OR 0.9 [0.6–1.4]). The
total incidence of microvascular disease
at the ﬁnal visit did not differ between
the GADA-positive and GADA-negative
participants (Table 5). Given the 17% rate
in microvascular diabetes complications in
Table 2—Clinical characteristics at baseline of GADA+ (hi), GADA+ (lo), and GADA2 individuals
Baseline GADA+ hi GADA+ lo GADA2
P GADA+ hi vs.
GADA2
P GADA+ lo vs.
GADA2
n 108 65 2,252
Age at diagnosis (years) 52.4 6 9.3 50.1 6 9.1 55.0 6 9.4 0.311 0.003
Duration of diabetes (years) 10.2 6 6.6 10.1 6 7.8 7.6 6 6.2 ,0.0001 0.0003
BMI (kg/m2) 27.0 6 3.8 27.9 6 3.4 28.9 6 3.5 ,0.0001 0.006
HbA1c (mmol/mol [%]) 70 6 16 (8.6 6 3.6%) 66 6 17 (8.2 6 3.2%) 62 6 15 (7.8 6 3.5%) ,0.0001 0.149
SBP (mmHg) 142.5 6 18.0 141.4 6 16.4 144.0 6 15.7 0.216 0.430
DBP (mmHg) 82.0 6 9.5 81.0 6 8.3 82.9 6 8.3 0.639 0.098
LDL cholesterol (mmol/L) 3.1 6 0.7 3.1 6 0.7 3.0 6 0.7 0.126 0.490
HDL cholesterol (mmol/L) 1.6 6 0.4 1.5 6 0.4 1.4 6 0.3 ,0.0001 0.107
CRP (mg/L) 3.1 6 6.2 2.2 6 2.6 3.1 6 6.4 0.345 0.189
Apolipoprotein A1 (mg/dL) 166.9 6 30.5 155.5 6 28.2 152.0 6 27.8 ,0.0001 0.494
Apolipoprotein B (mg/dL) 112.4 6 24.6 113.4 6 22.6 116.3 6 24.0 0.093 0.270
Atorvastatin treatment 48.2 50.8 51.0 0.487 0.869
High waist measure (WHO) 66.7 69.2 83.0 ,0.0001 0.006
Metabolic syndrome (IDF deﬁnition) 61.1 67.7 80.4 ,0.0001 0.025
Diet treated alone 3.7 9.2 15.7 0.017 0.566
Oral diabetes therapy 29.6 52.3 67.3 ,0.0001 0.041
Insulin treated alone 66.7 38.5 17.1 ,0.0001 0.004
Albuminuria+ (macro/micro) 13.0 6.2 11.6 0.689 0.173
Any retinopathy 34.3 36.9 29.4 0.697 0.891
Proliferative retinopathy 8.3 13.9 6.3 0.750 0.129
Current smoker 30.6 23.1 21.8 0.007 0.917
Use of BP tablets 57.4 61.5 67.5 0.026 0.521
Data are percent unless otherwise indicated. The clinical characteristics of the individuals in accordance with GADA positivity are presented as
means 6 SD. The data were analyzed pairwise for the GADA+ hi (GAD value .200 units) and GAD+ lo (GAD value 40–200 units) groups versus the
GADA2 group by multivariate analysis, adjusted for age, duration of diabetes, and sex.
Table 3—Follow-up by GADA status
Follow-up (4 years) GADA+ GADA2 Multivariate analysis
n 173 2,252
Cumulative use of insulin at year 4 follow-up n = 28 (16.2%) n = 114 (5.1%) 3.1 (2.0–4.9); 0.0001
Developed microvascular disease (albuminuria
or proliferative retinopathy) n = 35 (20.2%) n = 380 (16.9%) 0.9 (0.6–1.4); 0.7
Data are OR (95% CI); P value unless otherwise indicated. Follow-up data for GADA+ and GADA2 cases showing the cumulative use of insulin at 4
years’ follow-up as well as the development of microvascular disease, analyzed by multivariate analysis.
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GADA-negative patients, this study has
;80% power to detect a 9% or larger dif-
ference in the rate of complications
among GADA-positive patients. Only 13
GADA-positive patients had a CVD end
point. No statistical differencewas found
for the CVD end point by GAD status
(hazard ratio 1.36 [0.77–2.40]; Cox
model corrected for age and sex).
CONCLUSIONS
WHOclassiﬁes diabetes into the following
categories: type 1 diabetes, type 2 diabe-
tes, other causes, and gestational diabetes
mellitus. Currently, LADA is a subclassiﬁ-
cation of type 1 diabetes, since it is an
autoimmune disease and shares many
features in common with type 1 diabetes.
Unlike those with type 1 diabetes, people
diagnosed with LADA do not require im-
mediate insulin treatment, but the
presence of autoantibodies carries im-
plications for future insulin usage, as
shown here. Some suggest that LADA
patients should always be treated with
insulin; indeed, sulfonylureas may be
detrimental (16). However, there remains
uncertainty as to the clinical value of
screening for diabetes-associated auto-
antibodies in adult-onset diabetes.
This is the ﬁrst report of a large cohort
of patients with established diabetes
(mean initial disease duration 7.9 years)
analyzed for themajordiabetes-associated
autoantibodies and followed prospectively
for complications. From this analysis, we
learned that 7% of these patients had
GADA, that these GADA-positive case
subjects had a phenotype similar to that
previously reported for LADA (i.e., being
younger and leaner and more often
requiring insulin treatment than GADA-
negative cases), that GADA was the dom-
inant autoantibody; that on prospective
study (11.8 years postdiagnosis) a large
proportion of autoimmune diabetic pa-
tients still remain off insulin, and that
almost two-thirds of GADA-positive pa-
tients had the metabolic syndrome.
Furthermore, there was no marked dif-
ference in the risk of microvascular
complications between the two groups
and no history of smokingdthe latter
contrary to a recent report (15).
CARDS assessed the impact of ator-
vastatin on diabetes complications in a
cohort of patients (mean age 62 years)
with established type 2 diabetes and a
degree of cardiovascular risk. It was
surprising to discover that 7% of these
cases, despite their age and diabetes
duration (7.9 years postdiagnosis),
had diabetes-associated autoantibodies.
These autoantibody-positive cases, there-
fore, fulﬁlled the clinical diagnosis of
adult-onset autoimmune diabetes and
LADA (17). As with other large studies
of adult-onset diabetes, the predomi-
nant autoantibody in the CARDS cohort
was GADA, which here identiﬁed all
autoantibody-positive patients. A much
smaller proportion of cases (0.7%) had
IA-2A or ZnT8A, but all of these patients
also had GADA. The very low prevalence
of both IA-2A or ZnT8A in this CARDS
cohortwith establisheddiabetes contrasts
with that in cohorts with recent-onset
non–insulin-requiring diabetes, in line
with the results from the second survey
of the Norwegian HelseUndersøkelsen
i Nord-Trøndelag Study (HUNT2), as well
as the known tendency for both IA-2A
and ZnT8A to disappear postdiagnosis
(15,18–20). In HUNT2, 59% of LADA pa-
tients lost GADA on follow-up, but of
those who remained autoantibody posi-
tive all but one had GADA; IA-2A and
ZnT8A showed a decrease in the titer
over 10 years, but GADA titer did not de-
cline (21). We would, therefore, not rec-
ommend testing of either IA-2A or ZnT8A
in patients with established, compared
with newly diagnosed, type 2 diabetes.
Previous studies in China and Europe
have established that GADA-positive
adult-onset diabetic patients have an
HLA genetic susceptibility similar to
that of patients with childhood-onset
autoimmune type 1 diabetes (22,23).
Given immunogenetic similarities be-
tween childhood-onset and adult-onset
autoimmune diabetes, it is possible that
autoimmune diabetes is a continuous
spectrum with a broad clinical pheno-
type, which encompasses insulin-
dependent diabetes at one end of the
spectrum and non–insulin-dependent
diabetes at the other end. Two argu-
ments challenge this position. First,
GADA assays estimate signals with a
1% false positive rate. But in this study,
we limited that error by duplicating the
Table 4—Follow-up by GADA status
Follow-up (4 years) GADA+ hi GADA+ lo GADA2
Multivariate analysis
GADA+ hi vs. GADA2
Multivariate analysis
GADA+ lo vs. GADA2
n 108 65 2,252
Cumulative use of insulin
at year 4 follow-up n = 19 (17.6%) n = 9 (13.9%) n = 114 (5.1%)
3.5 (2.1–6.1);
,0.0001
2.5 (1.2–5.2);
0.018
Developed microvascular
disease (albuminuria or
proliferative retinopathy) n = 20 (18.5%) n = 15 (23.1%) n = 380 (16.9%) 0.8 (0.5–1.4); 0.415 1.2 (0.6–2.1); 0.644
Data are OR (95% CI); P value unless otherwise indicated. Follow-up data for GADA+ and GADA2 cases according to GADA titer showing the
cumulative use of insulin at 4 years’ follow-up as well as the development of microvascular disease, analyzed bymultivariate analysis. GADA+ hi, GAD
value .200 units; GADA+ lo, GAD value 40–200 units.
Table 5—Incidence of microvascular disease at ﬁnal visit by GADA status
Final visit (including year 5) GADA+ GADA2 Multivariate analysis
n 173 2,252
Microvascular disease (albuminuria
or proliferative retinopathy) n = 28 (16.2%) n = 315 (14.0%) 0.9 (0.6–1.4); 0.70
Microalbuminuria+ 11.3 12.5 0.7 (0.4–1.2); 0.19
Any retinopathy 31.2 26.3 0.9 (0.7–1.3); 0.68
Proliferative retinopathy 5.2 3.0 1.2 (0.6–2.5); 0.62
Data are % or OR (95% CI); P unless otherwise indicated. Microvascular disease at ﬁnal visit
between GADA+ and GADA2 cases; data analyzed by multivariate analysis.
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positive assays so that the error rate here
was ,0.02%, restricting the number of
false GADA positive cases. Second, since
GADA is not speciﬁc for autoimmune
diabetes, a positive result could reﬂect
an autoimmune tendency, independent
of diabetes. Yet, in all the major studies
of autoimmune diabetes, now amounting
to many thousands of patients, those
GADA-positive cases have a clinical phe-
notype different from that of the type 2
diabetic patients without GADA (15,22,24).
Speciﬁcally, GADA-positive patients with
adult-onset diabetes tend to have less
metabolic syndrome and higher HbA1c
and are more likely to be on insulin ther-
apy than GADA-negative patients with
type 2 diabetesddifferences even appar-
ent in patients with low-titer GADA. Given
that our present studywas cross-sectional,
we cannot exclude the possibility that
GADA appeared postdiagnosis, though
had that been the case it did not alter
the broad clinical features of these GADA-
positive patients. In other words, from
China to Europe, GADA positivity does
identify a consistent clinical phenotype, dif-
ferent from type 2 diabetes cases, indicat-
ing that GADA positivity is unlikely to be a
diabetes-independent epiphenomenon.
The CARDS cohort is the ﬁrst cohort of
reasonable size to be followed prospec-
tively for the development of diabetes
complications but is still underpowered
to detect anything other than very large
differences between the GADA-positive
and -negative patients. Since metabol-
ic syndrome is less prevalent in adult-
onset autoimmune diabetes than in
type 2 diabetes, one might anticipate
that those with the former are less prone
to both macrovascular and microvascular
complications. We found that the number
of macrovascular events was insufﬁcient
to give a meaningful result, but the rate
of progression to microvascular events
(i.e., the development of albuminuria or
proliferative retinopathy) was similar in
both types of diabetes.
Importantly, the higher HbA1c in the
autoimmune diabetic patients could be
sufﬁcient to offset the beneﬁts of having
less metabolic syndrome, lower blood
pressure, and less dyslipidemia. In CARDS,
even 10 years postdiagnosis, many auto-
immune diabetic patients are still not on
insulin treatment; but for those autoim-
mune patients on insulin, the HbA1c levels
were not lower than in type 2 diabetic
patients. A recent study also found that
such adult-onset autoimmune patients
tend to have higher HbA1c levels, even
when on insulin (8). So, putting recently
diagnosed adult-onset autoimmune
diabetes patients on insulin, as widely
practiced in centers in which the GADA
assay is available, does not predicate
good glucose control (25). Clearly, we
need to establish the optimum way to
treat adult-onset autoimmune diabetes
casesda point broadly missed when
engaging in semantic arguments about
the deﬁnitions of LADA and adult-onset
autoimmune diabetes. The present
study highlights limitations in our current
identiﬁcation and treatment of such
patients.
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